Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 14,176 | 12,395 |
| Selling and marketing | 12,221 | 8,465 |
| General and administrative | 27,684 | 25,291 |
| Amortization of intangible assets | 2,031 | 1,990 |
| Total operating expenses | 56,112 | 48,141 |
| Operating loss | (34,622) | (19,795) |
| Other income (expenses) | ||
| Interest income | 8,651 | 8,018 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s D&A?
- Fulgent Genetics, Inc. (FLGT) reported D&A of $2.03M in Q1 2026.
- How has Fulgent Genetics, Inc.'s D&A changed year-over-year?
- Fulgent Genetics, Inc.'s D&A increased by 2.1% year-over-year, from $1.99M to $2.03M.
- What is the long-term trend for Fulgent Genetics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s D&A has grown at a 7.3% compound annual growth rate (CAGR), from $6.05M to $8.03M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Fulgent Genetics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude